Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

October 23, 2018 10:37 AM | Anonymous

October 22, 2018, European Society for Medical Oncology via Medical Xpress  

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.  

Read more.

Powered by Wild Apricot Membership Software